Study of Sunitinib Malate in Patients With Newly Diagnosed Prostate Cancer Prior to Prostatectomy
Status:
Completed
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to look at blood and tissue samples for changes following the
use of Sunitinib malate. Additionally, we would like to find out if the drug, Sunitinib
malate, is safe and works in men with prostate cancer. Sunitinib malate , also known as
Sutent, is approved by the U.S. Food and Drug Administration (FDA), for treatment of tumors
of intestines and kidney but it is being tested in research studies for use in men with
prostate cancer.